

Deckel Number (Optional)
068911-0075

Application No : 10/789,814

FOR: SYNERGISTIC ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE

In making the above award, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patent granted on said reference application, as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to this application. The owner also disclaims the terminal part of any patent granted on said reference application that would extend to the expiration date of any patent granted on said reference application for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed, or is otherwise terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer, filed prior to its grant.

1. ☐ For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.

2. ☒ The undersigned is an attorney or agent of record. Reg. No. 59,037

Signatures

Atabak Royaneh

Typed or printed name

December 9, 2010
Date

Date:

(617) 535-4108
Telephone Number

☒ Terminal disclaimer fee under 37 CFR 1.20(d) is included

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner)

This collection of information is required by 37 CFR 1.351. The information is required to obtain or retain a benefit by the public entity is to the (and by the USPTO) including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any communication, including the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, 400 ...
ADDRESS: SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS-31-1450.**